Immunetx stock rises on trading day Tuesday for unclear reasons.
Introduction
Immuneering Corporation (NASDAQ: IMRX) has been making headlines with its recent updates on the Phase 2a trial of its lead program, IMM-1-104. The company revealed data from three pancreatic cancer arms of the ongoing trial, which has sent shockwaves through the market, causing Immuneering stock to surge higher.
Update on Phase 2a Trial
On Tuesday, Immuneering announced that it would be expanding the Phase 2a trial of IMM-1-104 to include three additional combination arms. This decision was made based on the promising data from the initial three pancreatic cancer arms of the trial.
Modified Gemcitabine/Nab-Paclitaxel Combination Arm
The updated data from the Phase 2a arm of IMM-1-104 with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer shows:
- As of December 5, 2024, three patients achieved complete or partial responses for an overall response rate of 43% (3/7) and a disease control rate of 86% (6/7)
- Four patients remain on treatment
For comparison, the Phase 3 MPACT study established benchmarks for gemcitabine/nab-paclitaxel alone in first-line pancreatic cancer patients, which included:
- A 23% Overall Response Rate
- A 48% Disease Control Rate
- Only 1 Complete Response (CR) out of 431 patients
The modified regimen used in the IMM-1-104 Phase 2 combination arm showed a more favorable response rate, with an 18.6% ORR.
Favorable Tolerability Profile
A favorable tolerability profile was observed for IMM-1-104 combined with modified Gemcitabine/nab-Paclitaxel. This is a significant finding, as it suggests that the combination of these two treatments may be effective and well-tolerated in first-line pancreatic cancer patients.
Combination with Modified FOLFIRINOX
The company also announced initial data from the Phase 2a arm of IMM-1-104 with modified FOLFIRINOX (mFFX) in first-line pancreatic cancer. The results showed:
- All evaluable patients (n=4) experienced target tumor shrinkage and disease control
- One patient achieved a 100% reduction (PR)
The combination of IMM-1-104 plus mFFX was generally well-tolerated, with the company currently evaluating the 320 mg QD dose of IMM-1-104 in combination with modified FOLFIRINOX.
Monotherapy in Second-Line Pancreatic Cancer
Immuneering also announced initial data from the Phase 2a arm of IMM-1-104 monotherapy in second-line pancreatic cancer. The results showed:
- Eleven of the twenty-one evaluable patients treated with IMM-1-104 as monotherapy achieved disease control, including one patient with 67% target lesion shrinkage
- Nine patients remain on treatment
The data suggests that IMM-1-104 may be highly suitable for both monotherapy and combination therapy in second-line pancreatic cancer.
Initial Pharmacokinetic, Pharmacodynamic, and Safety Data from Phase 1/2a Trial of IMM-6-415
Immuneering also announced initial pharmacokinetic, pharmacodynamic, and safety data from the Phase 1 portion of the company’s Phase 1/2a trial of IMM-6-415.
Future Data Expectations
The company says further IMM-1-104 Phase 2a data are expected in the second quarter of 2025. Additionally, Immuneering plans to expand the Phase 2a arms of IMM-1-104 to include three additional combination arms in 2025.
Price Action
IMRX stock is up 61.90% at $3.82 during the premarket session at last check Tuesday.
Conclusion
The recent updates from Immuneering Corporation have sent shockwaves through the market, causing its stock to surge higher. The promising data from the Phase 2a trial of IMM-1-104 has shown significant promise in treating pancreatic cancer, and the company’s decision to expand the trial to include additional combination arms is a positive step forward. As we move forward into the second quarter of 2025, investors will be eagerly awaiting further updates on Immuneering’s progress.
Stay ahead of the market with Benzinga Edge
Transform your trading with our one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today’s competitive market.
Get the latest stock analysis from Benzinga
This article, Why Is Immuneering Stock Trading Higher On Tuesday?, originally appeared on Benzinga.com. Benzinga does not provide investment advice. All rights reserved.